Monoclonal antibody extravasations: Two case reports and literature review
- 1 April 2021
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (3), 761-763
- https://doi.org/10.1177/1078155220950005
Abstract
Introduction Extravasation is a rare complication from intravenous chemotherapy administration. Literature about monoclonal antibody (MoAb) extravasations is scarce and also conflicting in how they are classified. Case report We reported two different cases of MoAb extravasations with cetuximab and nivolumab outcome respectively. The administration site appeared inflamed and patients did not report disturbances. Management and outcome:Both extravasations did not require specific treatment. General unspecific measures suffice to properly manage these extravasations and no sequels were observed after long follow-up. Both patients received all further courses of MoAb without any adverse events. Discussion To our knowledge, we reported the first case-report of nivolumab extravasation in the literature. In addition, the cetuximab extravasation management and outcome was in accordance with previously published reports. Both MoAb may be considered as non-aggressive or neutral. We reviewed published information about MoAb extravasations. In conclusion, not all MoAb should be classified in the same category when extravasated and special precautions are warranted with conjugated MoAb and bevacizumab.This publication has 8 references indexed in Scilit:
- Ultrasonographic assessment of an induration caused by extravasation of a nonvesicant anticancer drug A case reportMedicine, 2019
- Skin Necrosis After Ado-Trastuzumab Emtansine ExtravasationJournal of Oncology Practice, 2017
- Pharmacological management of anticancer agent extravasation: A single institutional guidelineJournal of Oncology Pharmacy Practice, 2017
- T‐DM1 extravasation: first descriptionJournal of the European Academy of Dermatology and Venereology, 2015
- Cervical extravasation of bevacizumabAnti-Cancer Drugs, 2013
- Cetuximab ExtravasationJournal of Pharmacy Practice and Research, 2013
- Management of chemotherapy extravasation: ESMO–EONS Clinical Practice GuidelinesAnnals of Oncology, 2012
- Case Report: Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin®): A Case ReportCancer Biotherapy & Radiopharmaceuticals, 2006